醒脑静注射液联合吡拉西坦治疗外伤性颅内出血临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R743.34

基金项目:


Clinical Study on Xingnaojing Injection Combined with Piracetam for Traumatic Intracranial Hemorrhage
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察醒脑静注射液联合吡拉西坦治疗外伤性颅内出血患者的临床疗效。方法:选取外伤性颅内出血患者68 例,随机分为对照组与治疗组各34 例。对照组给予吡拉西坦氯化钠注射液治疗,治疗组在对照组的基础上给予醒脑静注射液治疗。治疗1 个月后比较2 组临床疗效;并对2 组治疗前后认知功能[简易智能精神状态检查量表(MMSE) 评分]、日常生活能力量表(ADL) 评分、神经功能[美国国立卫生院神经功能缺损量表(NIHSS) 评分] 进行评估;检测2 组治疗前后血清肿瘤坏死因子-α (TNF-α)、超敏C-反应蛋白(hs-CRP)、白细胞介素-10(IL-10) 水平;观察2 组不良反应发生情况。结果:治疗组总有效率为100%,对照组为88.24%,2 组比较,差异有统计学意义(P<0.05)。治疗后,2 组MMSE、ADL 评分均较治疗前升高(P<0.05),且治疗组2 项评分均高于对照组(P<0.05)。治疗后,2 组NIHSS 评分均较治疗前降低(P<0.05),且治疗组评分低于对照组(P<0.05)。治疗后,2 组血清TNF-α、hs-CRP、IL-10 水平均较治疗前降低(P<0.05),且治疗组上述各项指标低于对照组(P<0.05)。治疗组不良反应发生率为11.76%,对照组为8.82%,2 组比较,差异无统计学意义(P>0.05)。结论:醒脑静注射液联合吡拉西坦治疗外伤性颅内出血能提高临床疗效,有效保护患者认知与神经功能,提高其生活能力,改善炎症因子水平,减少后遗症的发生。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Xingnaojing injection combined with piracetam for traumatic intracranial hemorrhage. Methods: A total of 68 cases of patients with traumatic intracranial hemorrhage were randomly divided into the control group and the treatment group,34 cases in each group. The control group was treated with piracetam sodium chloride injection,and the treatment group was additionally given Xingnaojing injection based on the treatment of the control group. After one month of treatment,the clinical effect in the two groups was compared. Before and after treatment, the cognitive function(MMSE scores),activity of daily living(ADL scores) and neurological function(NIHSS scores) in the two groups were evaluated; the levels of tumor necrosis factor- α(TNF- α), hypersensitive C- reactive protein(hs- CRP) and interleukin-10(IL-10) in serum in the two groups were detected;the incidence of adverse reactions in the two groups was observed. Results:The total effective rate was 100% in the treatment group and 88.24% in the control group,the difference being significant(P<0.05). After treatment,the scores of MMSE and ADL in the two groups were increased when compared with those before treatment(P<0.05),and the above two scores in the treatment group were higher than those in the control group(P<0.05). After treatment, NIHSS scores in the two groups were decreased when compared with those before treatment(P<0.05),and the score in the treatment group was lower than that in the control group(P<0.05). After treatment, the levels of TNF- α, hs- CRP and IL- 10 in serum in the two groups were decreased when compared with those before treatment(P<0.05),and the above indexes in the treatment group were lower than those in the control group(P<0.05). The incidence of adverse reactions was 11.76% in the treatment group, and 8.82% in the control group, there being no significance in the difference(P>0.05). Conclusion:Xingnaojing injection combined with piracetam for traumatic intracranial hemorrhage can improve the clinical effect,effectively protect the cognitive and neurological functions of patients,enhance their activity of daily living,improve the levels of inflammatory factors,and reduce the occurrence of sequela.

    参考文献
    相似文献
    引证文献
引用本文

何宇刚,周飞铖,杨新龙.醒脑静注射液联合吡拉西坦治疗外伤性颅内出血临床研究[J].新中医,2021,53(10):81-84

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-05-24
  • 出版日期:
文章二维码